Molecularly Adapted Antitumor Therapy for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Two-Year Follow-Up Results

医学 内科学 肿瘤科 不利影响 靶向治疗 人口 淋巴瘤 总体生存率 基因分型 外科 阶段(地层学) 完全响应 恶性肿瘤 不良事件通用术语标准 临床终点 回顾性队列研究
作者
Marat Albertovich Mingalimov,Elena Alexandrovna Baryakh,Andrey Misyurin,Л. А. Кесаева,Hasmik Mkrtchyan,Elena N Misyurina,Mariia Orlova,Tatiana Tolstykh,Ekaterina Zotina,L. T. Shimanovskaya,Т. С. Чуднова,Diana Ivanova,О. Л. Кочнева,Кseniya Tsurkina,Dmitry Lebedev,Georgii Tyshkevich,Natalia Bekreneva,Viktoriia Basova,Mikhail Donskoy,Sergej Rodnikov
出处
期刊:Journal of Clinical Medicine [Multidisciplinary Digital Publishing Institute]
卷期号:15 (8): 2983-2983 被引量:1
标识
DOI:10.3390/jcm15082983
摘要

Background/Objectives: Diffuse large B-cell lymphoma (DLBCL) is molecularly heterogeneous, and approximately 30-50% of patients fail to achieve cure with standard R-CHOP. Genotype-directed first-line therapy may improve outcomes by targeting subtype-specific oncogenic pathways. This study evaluated the feasibility, efficacy, and safety of a molecularly adapted R-CHOP-X strategy with two-year follow-up. Methods: In this single-center, prospective, non-randomized study conducted between September 2023 and the data cut-off (16 September 2025), 43 adults with newly diagnosed DLBCL (excluding high-grade B-cell lymphoma, primary immune-privileged, and primary mediastinal large B-cell lymphomas) underwent tumor genotyping using the LymphGen classification after targeted sequencing: a 19-gene Sanger panel (Cohort 1, n = 35) or an expanded 60-gene panel (Cohort 2, n = 8; proof-of-concept). All patients received one initial cycle of R-CHOP as bridge therapy pending molecular profiling results, followed by five cycles of R-CHOP-X, with the additional agent (vorinostat, acalabrutinib, decitabine, or lenalidomide) selected according to molecular subtype. Response was assessed by PET/CT per Lugano criteria; adverse events were graded per NCI CTCAE v5.0. Results: The overall study population was predominantly high-risk: 72% had an IPI of 3–5, 58% had stage III–IV disease, and 67% exhibited a non-GCB immunophenotype. Expansion from the 19-gene to the 60-gene panel reduced unclassifiable (NOS) cases from 34% to 12%. The overall response rate was 100% (43/43); complete response among patients completing therapy was 100% (35/35). At two years, overall survival was 92% (95% CI 83–100%) and progression-free survival was 94% (95% CI 86–100%). Two early relapses occurred (NOS and N1 subtypes), both resulting in death. Grade 3–4 neutropenia, thrombocytopenia, and anemia occurred in 26%, 12%, and 7% of patients, respectively; no dose reductions or treatment discontinuations were recorded. Conclusions: Molecularly adapted R-CHOP-X is feasible and associated with high response rates and favorable two-year survival in newly diagnosed DLBCL, comparing favorably with historical R-CHOP outcomes in high-risk populations. Expanded genomic panels substantially improve molecular classifiability. These findings warrant validation in larger, multicenter, randomized clinical trials.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大个的应助被东风知我欲采纳,获得30
2秒前
3秒前
youknowdcf发布了新的文献求助10
3秒前
Akim的应助被yiyi1采纳,获得20
3秒前
3秒前
4秒前
zhouyang发布了新的文献求助10
4秒前
5秒前
7秒前
田様的应助被xxxg郭采纳,获得10
8秒前
汉堡包的应助被cc采纳,获得10
8秒前
虾米君完成签到,获得积分10
8秒前
9秒前
溜溜梅棒棒棒完成签到,获得积分10
9秒前
FashionBoy的应助被motal采纳,获得10
9秒前
春风失意发布了新的文献求助10
10秒前
耶稣与梦完成签到,获得积分10
11秒前
Pao完成签到,获得积分10
11秒前
ZXheng完成签到,获得积分10
12秒前
12秒前
14秒前
DW的应助被汤易文采纳,获得10
14秒前
14秒前
mugi3055完成签到 ,获得积分10
14秒前
zhangpeiguo完成签到,获得积分10
16秒前
Ariel发布了新的文献求助10
16秒前
16秒前
17秒前
沉默笑翠完成签到,获得积分10
18秒前
爆米花的应助被youknowdcf采纳,获得10
19秒前
19秒前
西陆发布了新的文献求助10
19秒前
JeanetteJin发布了新的文献求助10
20秒前
20秒前
哒哒完成签到,获得积分10
20秒前
20秒前
cc完成签到,获得积分10
21秒前
蔡翌文完成签到 ,获得积分10
21秒前
NASA_FAST发布了新的文献求助30
21秒前
zhouyang完成签到,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177667
求助须知:如何正确求助?哪些是违规求助? 9568537
关于积分的说明 21799700
捐赠科研通 7772307
什么是DOI,文献DOI怎么找? 3432429
关于科研通互助平台的介绍 2556651
邀请新用户注册赠送积分活动 2478011